Recruiting
Phase III Trans-Arterial Chemo-Embolization (TACE) Adjuvant HCC
Conditions: Hepatocellular Carcinoma
Interventions: Drug: Brivanib, Drug: Brivanib Placebo
Phase: Phase III
Conditions: Hepatocellular Carcinoma
Interventions: Drug: Brivanib, Drug: Brivanib Placebo
Phase: Phase III
Recruiting
Adjuvant Therapy With Thalidomide for Chemoembolization in Advanced Hepatocellular Carcinoma
Conditions: Hepatocellular Carcinoma
Interventions: Drug: Thalidomide, Drug: TACE
Phase: Phase III
Conditions: Hepatocellular Carcinoma
Interventions: Drug: Thalidomide, Drug: TACE
Phase: Phase III
Recruiting
Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery
Conditions: Liver Cancer
Interventions: Drug: cisplatin, Drug: doxorubicin hydrochloride, Drug: doxorubicin-eluting beads, Drug: mitomycin C, Drug: sorafenib tosylate, Other: placebo
Phase: Phase III
Conditions: Liver Cancer
Interventions: Drug: cisplatin, Drug: doxorubicin hydrochloride, Drug: doxorubicin-eluting beads, Drug: mitomycin C, Drug: sorafenib tosylate, Other: placebo
Phase: Phase III
Recruiting
Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Conditions: Liver Cancer
Interventions: Drug: doxorubicin hydrochloride, Drug: sorafenib tosylate
Phase: Phase III
Conditions: Liver Cancer
Interventions: Drug: doxorubicin hydrochloride, Drug: sorafenib tosylate
Phase: Phase III
Recruiting
Global Study Looking at the Combination of RAD001 Plus Best Supportive Care (BSC) and Placebo Plus BSC to Treat Patients With Advanced Hepatocellular Carcinoma.
Conditions: Carcinoma
Interventions: Drug: Everolimus
Phase: Phase III
Conditions: Carcinoma
Interventions: Drug: Everolimus
Phase: Phase III
Recruiting
Comparison of Brivanib and Best Supportive Care to Placebo for Treatment of Liver Cancer for Asian Subjects Who Have Failed Sorafenib Treatment
Conditions: Carcinoma, Hepatocellular
Interventions: Drug: Brivanib, Drug: Placebo
Phase: Phase III
Conditions: Carcinoma, Hepatocellular
Interventions: Drug: Brivanib, Drug: Placebo
Phase: Phase III
Recruiting
A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Patients With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib
Conditions: Hepatocellular Carcinoma
Interventions: Biological: Placebo, Biological: Ramucirumab DP (IMC-1121B)
Phase: Phase III
Conditions: Hepatocellular Carcinoma
Interventions: Biological: Placebo, Biological: Ramucirumab DP (IMC-1121B)
Phase: Phase III
Recruiting
Comparing Efficacy of Sorafenib Versus Sorafenib in Combination With Low-dose FP in Patients With Advanced HCC
Conditions: Advanced Hepatocellular Carcinoma, Carcinoma, Carcinoma, Hepatocellular, Liver Neoplasms, Neoplasms
Interventions: Drug: Sorafenib with Low-dose FP, Drug: Sorafenib
Phase: Phase III
Conditions: Advanced Hepatocellular Carcinoma, Carcinoma, Carcinoma, Hepatocellular, Liver Neoplasms, Neoplasms
Interventions: Drug: Sorafenib with Low-dose FP, Drug: Sorafenib
Phase: Phase III
Recruiting
Transarterial Chemoembolization Using Doxorubicin Beads With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery
Conditions: Liver Cancer
Interventions: Drug: doxorubicin-eluting beads, Drug: sorafenib tosylate, Other: laboratory biomarker analysis, Other: pharmacogenomic studies, Other: pharmacological study, Procedure: quality-of-life assessment
Phase: Phase III
Conditions: Liver Cancer
Interventions: Drug: doxorubicin-eluting beads, Drug: sorafenib tosylate, Other: laboratory biomarker analysis, Other: pharmacogenomic studies, Other: pharmacological study, Procedure: quality-of-life assessment
Phase: Phase III
Recruiting
A Phase III Study of PI-88 in the Adjuvant Treatment of Subjects With Hepatitis Virus Related Hepatocellular Carcinoma After Surgical Resection
Conditions: Cancer, Liver Cancer, Hepatocellular Carcinoma
Interventions: Drug: PI-88, Other: Placebo
Phase: Phase III
Conditions: Cancer, Liver Cancer, Hepatocellular Carcinoma
Interventions: Drug: PI-88, Other: Placebo
Phase: Phase III
Recruiting
Sorafenib in First-line Treatment of Advanced B Child Hepatocellular Carcinoma
Conditions: Advanced Adult Hepatocellular Carcinoma
Interventions: Other: Best Supportive Care, Drug: sorafenib
Phase: Phase III
Conditions: Advanced Adult Hepatocellular Carcinoma
Interventions: Other: Best Supportive Care, Drug: sorafenib
Phase: Phase III
Recruiting
Orantinib In Combination With Transcatheter Arterial Chemoembolization In Patients With Unresectable Hepatocellular Carcinoma
Conditions: Hepatocellular Carcinoma
Interventions: Drug: Orantinib (TSU-68), Drug: Placebo
Phase: Phase III
Conditions: Hepatocellular Carcinoma
Interventions: Drug: Orantinib (TSU-68), Drug: Placebo
Phase: Phase III
Recruiting
SorAfenib Versus RADIOEMBOLIZATION in Advanced Hepatocellular Carcinoma
Conditions: Liver Carcinoma
Interventions: Drug: sorafenib, Drug: SIR-Sphere
Phase: Phase III
Conditions: Liver Carcinoma
Interventions: Drug: sorafenib, Drug: SIR-Sphere
Phase: Phase III
Recruiting
Study to Compare Selective Internal Radiation Therapy (SIRT) Versus Sorafenib in Locally Advanced Hepatocellular Carcinoma (HCC)
Conditions: Hepatocellular Carcinoma
Interventions: Device: SIR-Spheres, Drug: Sorafenib tosylate
Phase: Phase III
Conditions: Hepatocellular Carcinoma
Interventions: Device: SIR-Spheres, Drug: Sorafenib tosylate
Phase: Phase III
Recruiting
Vandetanib Gemcitabine Or Placebo Plus Gemcitabine Or Vandetanib Monotherapy In Advanced Biliary Tract Cancer
Conditions: Biliary Tract Cancer, Gallbladder Cancer, Cancer Of The Extrahepatic Bile Duct, Ampullary Carcinoma
Interventions: Drug: ZD6474, VANDETANIB, Drug: ZD6474, VANDETANIB, Drug: GEMCITABINE, Drug: Placebo matching ZD6474
Phase: Phase II
Conditions: Biliary Tract Cancer, Gallbladder Cancer, Cancer Of The Extrahepatic Bile Duct, Ampullary Carcinoma
Interventions: Drug: ZD6474, VANDETANIB, Drug: ZD6474, VANDETANIB, Drug: GEMCITABINE, Drug: Placebo matching ZD6474
Phase: Phase II
Recruiting
Sorafenib Therapy Prior to Radiofrequency Ablation for Intermediate Sized Hepatocellular Cancer
Conditions: Hepatocellular Cancer
Interventions: Drug: Sorafenib or Placebo, Procedure: Radiofrequency Ablation
Phase: Phase II
Conditions: Hepatocellular Cancer
Interventions: Drug: Sorafenib or Placebo, Procedure: Radiofrequency Ablation
Phase: Phase II
Recruiting
Bevacizumab and Erlotinib or Sorafenib as First-Line Therapy in Treating Patients With Advanced Liver Cancer
Conditions: Liver Cancer
Interventions: Biological: bevacizumab, Drug: erlotinib hydrochloride, Drug: sorafenib tosylate
Phase: Phase II
Conditions: Liver Cancer
Interventions: Biological: bevacizumab, Drug: erlotinib hydrochloride, Drug: sorafenib tosylate
Phase: Phase II
Recruiting
A Study of IMC-A12 in Combination With Sorafenib in Patients With Advanced Cancer of the Liver
Conditions: Hepatocellular Carcinoma
Interventions: Biological: IMC-A12 (cixutumumab), Biological: IMC-A12 (cixutumumab), Drug: sorafenib
Phase: Phase II
Conditions: Hepatocellular Carcinoma
Interventions: Biological: IMC-A12 (cixutumumab), Biological: IMC-A12 (cixutumumab), Drug: sorafenib
Phase: Phase II
Recruiting
4SC-201 and Sorafenib in Advanced Hepatocellular Carcinoma
Conditions: Hepatocellular Carcinoma
Interventions: Drug: 4SC-201, Drug: Sorafenib
Phase: Phase II
Conditions: Hepatocellular Carcinoma
Interventions: Drug: 4SC-201, Drug: Sorafenib
Phase: Phase II
Recruiting
A Phase II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients
Conditions: Carcinoma, Hepatocellular
Interventions: Drug: Sorafenib, Drug: BIBF 1120
Phase: Phase II
Conditions: Carcinoma, Hepatocellular
Interventions: Drug: Sorafenib, Drug: BIBF 1120
Phase: Phase II
Recruiting
Phase I/II Comparison of Efficacy and Safety of BIBF 1120 and Sorafenib in Patients With Advanced Hepatocellular Carcinoma
Conditions: Carcinoma, Hepatocellular
Interventions: Drug: BIBF 1120, Drug: BIBF 1120, Drug: Sorafenib, Drug: Sorafenib
Phase: Phase II
Conditions: Carcinoma, Hepatocellular
Interventions: Drug: BIBF 1120, Drug: BIBF 1120, Drug: Sorafenib, Drug: Sorafenib
Phase: Phase II
Recruiting
Sorafenib Tosylate With or Without Everolimus in Treating Patients With Localized, Unresectable, or Metastatic Liver Cancer
Conditions: Liver Cancer
Interventions: Drug: everolimus, Drug: sorafenib tosylate, Other: questionnaire administration, Procedure: computed tomography, Procedure: magnetic resonance imaging, Procedure: quality-of-life assessment
Phase: Phase II
Conditions: Liver Cancer
Interventions: Drug: everolimus, Drug: sorafenib tosylate, Other: questionnaire administration, Procedure: computed tomography, Procedure: magnetic resonance imaging, Procedure: quality-of-life assessment
Phase: Phase II
Recruiting
Phase II Trial of Sorafenib in Combination With Capecitabine for the Treatment of Patients With Measurable Hepatocellular Carcinoma
Conditions: Hepatocellular Carcinoma
Interventions: Drug: Sorafenib, Capecitabine
Phase: Phase II
Conditions: Hepatocellular Carcinoma
Interventions: Drug: Sorafenib, Capecitabine
Phase: Phase II
Recruiting
Trial of Transcatheter Arterial Chemoembolization (TACE) With Sorafenib for Locally Advanced Hepatocellular Carcinoma (HCC)
Conditions: Hepatocellular Carcinoma
Interventions: Drug: Sorafenib, Procedure: TACE (Transcatheter arterial chemoembolization)
Phase: Phase II
Conditions: Hepatocellular Carcinoma
Interventions: Drug: Sorafenib, Procedure: TACE (Transcatheter arterial chemoembolization)
Phase: Phase II
Recruiting
Comparison Study of Sorafenib and 5-fluorouracil/Mitomycin for Metastatic Hepatocellular Carcinoma
Conditions: Carcinoma, Hepatocellular
Interventions: Drug: 5-FU, Drug: Mitomycin, Drug: sorafenib
Phase: Phase II
Conditions: Carcinoma, Hepatocellular
Interventions: Drug: 5-FU, Drug: Mitomycin, Drug: sorafenib
Phase: Phase II
Recruiting
A Study of Recombinant Vaccinia Virus Prior to Sorafenib to Treat Unresectable Primary Hepatocellular Carcinoma
Conditions: Carcinoma, Hepatocellular
Interventions: Drug: JX-594 followed by sorafenib
Phase: Phase II
Conditions: Carcinoma, Hepatocellular
Interventions: Drug: JX-594 followed by sorafenib
Phase: Phase II
Recruiting
Erlotinib Plus Bevacizumab in Hepatocellular Carcinoma (HCC) as Second-line Therapy
Conditions: Liver Cancer
Interventions: Drug: Bevacizumab, Drug: Erlotinib
Phase: Phase II
Conditions: Liver Cancer
Interventions: Drug: Bevacizumab, Drug: Erlotinib
Phase: Phase II
Recruiting
Axitinib For The Treatment Of Advanced Hepatocellular Carcinoma
Conditions: Hepatocellular Carcinoma
Interventions: Drug: Axitinib (AG-013736), Drug: Placebo
Phase: Phase II
Conditions: Hepatocellular Carcinoma
Interventions: Drug: Axitinib (AG-013736), Drug: Placebo
Phase: Phase II
Recruiting
Cediranib Maleate and Combination Chemotherapy in Treating Patients With Advanced Biliary Cancers
Conditions: Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Liver Cancer, Periampullary Adenocarcinoma
Interventions: Drug: AZD2171, Drug: mFOLFOX6
Phase: Phase II
Conditions: Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Liver Cancer, Periampullary Adenocarcinoma
Interventions: Drug: AZD2171, Drug: mFOLFOX6
Phase: Phase II
Recruiting
A Study of Dovitinib Versus Sorafenib in Adult Patients With Hepatocellular Carcinoma (HCC) as a First Line Treatment
Conditions: Hepatocellular Carcinoma
Interventions: Drug: dovitinib, Drug: sorafenib
Phase: Phase II
Conditions: Hepatocellular Carcinoma
Interventions: Drug: dovitinib, Drug: sorafenib
Phase: Phase II
Recruiting
MK2206 in Treating Patients With Advanced Liver Cancer That Did Not Respond to Previous Therapy
Conditions: Liver Cancer
Interventions: Drug: Akt inhibitor MK2206, Other: laboratory biomarker analysis
Phase: Phase II
Conditions: Liver Cancer
Interventions: Drug: Akt inhibitor MK2206, Other: laboratory biomarker analysis
Phase: Phase II
Recruiting
A Study of LY2157299 in Patients With Hepatocellular Carcinoma
Conditions: Carcinoma, Hepatocellular
Interventions: Drug: LY2157299
Phase: Phase II
Conditions: Carcinoma, Hepatocellular
Interventions: Drug: LY2157299
Phase: Phase II
Recruiting
Clinical Study of Sorafenib and Zoledronic Acid to Treat Advanced HCC
Conditions: Hepatocellular Carcinoma
Interventions: Drug: Sorafenib and Zoledronic Acid
Phase: Phase II
Conditions: Hepatocellular Carcinoma
Interventions: Drug: Sorafenib and Zoledronic Acid
Phase: Phase II
Recruiting
Study of Sorafenib With or Without VT-122 in Patients With Hepatocellular Carcinoma (HCC)
Conditions: Hepatocellular Carcinoma
Interventions: Drug: Sorafenib, Drug: VT-122 (propranolol plus etodolac), Drug: Placebo
Phase: Phase II
Conditions: Hepatocellular Carcinoma
Interventions: Drug: Sorafenib, Drug: VT-122 (propranolol plus etodolac), Drug: Placebo
Phase: Phase II
Recruiting
Sorafenib Plus Doxorubicin Versus Sorafenib Alone for the Treatment of Advanced Hepatocellular Carcinoma: a Randomized Phase II Trial
Conditions: Advanced Hepatocellular Carcinoma (HCC) Stage C According to BCLC Classification Restricted to Child-Pugh Class A/B (5-7 Points).
Interventions: Drug: Doxorubicin, Drug: Sorafenib
Phase: Phase II
Conditions: Advanced Hepatocellular Carcinoma (HCC) Stage C According to BCLC Classification Restricted to Child-Pugh Class A/B (5-7 Points).
Interventions: Drug: Doxorubicin, Drug: Sorafenib
Phase: Phase II
Recruiting
Axitinib as Second-line Treatment for Advanced Hepatocellular Carcinoma
Conditions: Hepatocellular Carcinoma
Interventions: Drug: AG-013736
Phase: Phase II
Conditions: Hepatocellular Carcinoma
Interventions: Drug: AG-013736
Phase: Phase II
Recruiting
Study of Pegylated Liposomal Doxorubicin and Temsirolimus in Patients With Advanced Hepatocellular Cancer
Conditions: Liver Neoplasms
Interventions: Drug: Temsirolimus 25mg and Pegylated liposomal doxorubicin 25mg/m2
Phase: Phase II
Conditions: Liver Neoplasms
Interventions: Drug: Temsirolimus 25mg and Pegylated liposomal doxorubicin 25mg/m2
Phase: Phase II
Recruiting
Evaluating the Safety and Efficacy of SB Injection in Patients With Advanced or Primary Hepatocellular Carcinoma (HCC)
Conditions: Hepatocellular Carcinoma
Interventions: Drug: SB injection
Phase: Phase II
Conditions: Hepatocellular Carcinoma
Interventions: Drug: SB injection
Phase: Phase II
Recruiting
Study of Axitinib in Patients With Unresectable Hepatocellular Carcinoma
Conditions: Hepatocellular Carcinoma
Interventions: Drug: Axitinib (AG-013736)
Phase: Phase II
Conditions: Hepatocellular Carcinoma
Interventions: Drug: Axitinib (AG-013736)
Phase: Phase II
Recruiting
A Phase II Trial of OSI-906 and Sorafenib in Advanced Hepatocellular Cancer
Conditions: Liver Cancer
Interventions: Drug: Sorafenib and OSI-906
Phase: Phase II
Conditions: Liver Cancer
Interventions: Drug: Sorafenib and OSI-906
Phase: Phase II
Recruiting
Hepatocellular Carcinoma (HCC) Transarterial Chemoembolisation (TACE) +Axitinib
Conditions: Hepatocellular Carcinoma
Interventions: Drug: Axitinib
Phase: Phase II
Conditions: Hepatocellular Carcinoma
Interventions: Drug: Axitinib
Phase: Phase II
Recruiting
Efficacy of Sirolimus In Liver Transplantation for Hepatocellular Carcinoma (HCC)
Conditions: Hepatocellular Carcinoma
Interventions: Drug: Sirolimus, Drug: m-TOR inhibitor free
Phase: Phase II
Conditions: Hepatocellular Carcinoma
Interventions: Drug: Sirolimus, Drug: m-TOR inhibitor free
Phase: Phase II
Recruiting
TRC105 for Liver Cancer That Has Not Responded to Sorafenib
Conditions: Hepatocellular Carcinoma, Hepatocellular Cancer, Carcinoma, Hepatocellular
Interventions: Drug: TRC105
Phase: Phase II
Conditions: Hepatocellular Carcinoma, Hepatocellular Cancer, Carcinoma, Hepatocellular
Interventions: Drug: TRC105
Phase: Phase II
Recruiting
MK2206 in Treating Patients With Advanced Refractory Biliary Cancer That Cannot Be Removed by Surgery
Conditions: Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Liver Cancer
Interventions: Drug: Akt inhibitor MK2206, Genetic: mutation analysis, Genetic: proteomic profiling, Other: laboratory biomarker analysis, Other: pharmacogenomic studies, Other: pharmacological study
Phase: Phase II
Conditions: Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Liver Cancer
Interventions: Drug: Akt inhibitor MK2206, Genetic: mutation analysis, Genetic: proteomic profiling, Other: laboratory biomarker analysis, Other: pharmacogenomic studies, Other: pharmacological study
Phase: Phase II
Recruiting
Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer
Conditions: Head and Neck Cancer, Kidney Cancer, Liver Cancer, Sarcoma
Interventions: Drug: sorafenib tosylate, Genetic: gene expression analysis, Genetic: mutation analysis, Genetic: polymerase chain reaction, Other: enzyme-linked immunosorbent assay, Other: laboratory biomarker analysis, Other: pharmacological study
Phase: Phase II
Conditions: Head and Neck Cancer, Kidney Cancer, Liver Cancer, Sarcoma
Interventions: Drug: sorafenib tosylate, Genetic: gene expression analysis, Genetic: mutation analysis, Genetic: polymerase chain reaction, Other: enzyme-linked immunosorbent assay, Other: laboratory biomarker analysis, Other: pharmacological study
Phase: Phase II
Recruiting
Neoadjuvant Sorafenib Therapy Prior to Laser Ablation for Hepatocellular Carcinoma
Conditions: Hepatocellular Carcinoma
Interventions: Drug: Sorafenib, Procedure: laser ablation (LA)
Phase: Phase II
Conditions: Hepatocellular Carcinoma
Interventions: Drug: Sorafenib, Procedure: laser ablation (LA)
Phase: Phase II
Not yet recruiting
Palliative Treatment of Hepatocellular Carcinoma in Patient With CHILD B Cirrhosis
Conditions: Hepatocellular Carcinoma, CHILD B
Interventions: Drug: sorafenib, Drug: Pravastatin, Drug: Sorafenib + Pravastatin, Other: patients receiving best supportive care
Phase: Phase II
Conditions: Hepatocellular Carcinoma, CHILD B
Interventions: Drug: sorafenib, Drug: Pravastatin, Drug: Sorafenib + Pravastatin, Other: patients receiving best supportive care
Phase: Phase II
Not yet recruiting
Safety and Efficacy of RAD001 + TACE in Localized Unresectable HCC
Conditions: Hepatocellular Carcinoma
Interventions: Drug: everolimus, Drug: everolimus placebo
Phase: Phase II
Conditions: Hepatocellular Carcinoma
Interventions: Drug: everolimus, Drug: everolimus placebo
Phase: Phase II
Not yet recruiting
Sorafenib Versus TACE in Hepatocellular Carcinoma (HCC) With Portal Vein Invasion
Conditions: Hepatocellular Carcinoma
Interventions: Drug: Sorafenib, Procedure: TACE for HCC with portal vein invasion
Phase: Phase II
Conditions: Hepatocellular Carcinoma
Interventions: Drug: Sorafenib, Procedure: TACE for HCC with portal vein invasion
Phase: Phase II
Not yet recruiting
Everolimus and Pasireotide (SOM230) in Patients With Advanced or Metastatic Hepatocellular Carcinoma
Conditions: Advanced Adult Hepatocellular Carcinoma
Interventions: Drug: Everolimus, Drug: Pasireotide
Phase: Phase II
Conditions: Advanced Adult Hepatocellular Carcinoma
Interventions: Drug: Everolimus, Drug: Pasireotide
Phase: Phase II
Not yet recruiting
A Study of RO5137382 (GC33) in Patients With Advanced or Metastatic Hepatocellular Carcinoma
Conditions: Liver Cancer
Interventions: Drug: RO5137382, Drug: Placebo
Phase: Phase II
Conditions: Liver Cancer
Interventions: Drug: RO5137382, Drug: Placebo
Phase: Phase II
Clinical Trial Data provided by http://www.clinicaltrials.gov.